Penumbra jumps on Boston Scientific's $14.5 billion buyout

Shares of medical equipment maker Penumbra PEN.N rise 12.1% to $351.32

Boston Scientific says it will buy Penumbra in a deal valued at about $14.5 billion

The transaction values each Penumbra share at $374, a premium of 19.3% to the stock's last close

Boston Scientific BSX.N falls 4.2% to $89.7

"We think there will be two schools of thought from the Boston Scientific perspective, with Penumbra investors likely to be very pleased with the (per share) purchase price" J.P. Morgan analysts say

The deal is expected to be completed later this year

"From a strategic standpoint this makes a ton of sense for BSX to fully commit to getting into the thrombectomy market, which is one of the last MedTech frontiers that is highly unpenetrated with a significant growth runway" Bernstein analyst Christian Moore says

BSX shares rose 6.75%, PEN rose 29.6% in 2025